The North America Neurological Biomarkers Market would witness market growth of 13.5% CAGR during the forecast period (2022-2028).
Biomarkers, which are molecules that demonstrate the presence of a disease or dysfunction, are crucial for verifying diagnoses, selecting the most effective therapies, and tracking the development of diseases. Biomarkers for neurological disorders are one exception. Neurological markers can be found in cerebrospinal fluid (CSF), but seldom or in undetectable concentrations in blood.
The blood-brain barrier, which acts as the brain's own personal "security guard," closely monitors it to prevent harmful substances from entering it through the bloodstream. CSF can be used for neurological biomarkers, although doing so necessitates an invasive and uncomfortable lumbar puncture technique. These mysterious neural biomarkers are, nevertheless, gradually becoming clear. Neurological illnesses are becoming more manageable due to recent advancements in detection as well as the complete power of groupings of biomarkers, or biomarker signatures.
Using biomarkers as trial surrogate endpoints has a variety of benefits. The use of primary clinical outcomes in clinical trials can be extremely impractical or even unethical because they can occur so seldom, such as survival. Clear clinical objectives for many diseases, like survival or the recurrence of, say, a cardiovascular incident, may not emerge for many years after starting treatment. As more conclusive clinical data is gathered, biomarkers can give researchers interim information about the efficacy and safety of such treatments.
In the North American region, neurological problems are becoming more prevalent. Healthcare practitioners are making efforts to treat these conditions more effectively. Elderly people are becoming more prevalent in the neighborhood as well. By 2060, there will be 95 million Americans 65 and older, up from 52 million in 2018, due to increased R&D activities in the healthcare sector and the availability of neuromodulation devices on the market. The market is growing as more healthcare organizations invest in research and development.
The US market dominated the North America Neurological Biomarkers Market by Country in 2021; thereby, achieving a market value of $3,528.3 Million by 2028. The Canada market is exhibiting a CAGR of 16.1% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 15% during (2022 - 2028).
Based on Type, the market is segmented into Proteomic, Genomic, Metabolomic and Others. Based on Application, the market is segmented into Alzheimer's Disease, Parkinson’s Disease and Multiple Sclerosis. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Neurological Biomarkers Market is Predict to reach $12.9 Billion by 2028, at a CAGR of 14.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include F. HOFFMANN-LA ROCHE LTD., Bio-Rad Laboratories, Inc., Merck Group, PERKINELMER INC., Shimadzu corporation, Thermo Fisher Scientific, Inc., Quanterix Corporation, Neuro-Bio Ltd., BioMérieux S.A. and Myriad Genetics, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Type
- Proteomic
- Genomic
- Metabolomic
- Others
By Application
- Alzheimer's Disease
- Parkinson’s Disease
- Multiple Sclerosis
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- F.HOFFMANN-LA ROCHE LTD.
- Bio-Rad Laboratories, Inc.
- Merck Group
- PERKINELMER INC.
- Shimadzu corporation
- Thermo Fisher Scientific, Inc.
- Quanterix Corporation
- Neuro-Bio Ltd.
- BioMérieux S.A.
- Myriad Genetics, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Neurological Biomarkers Market, by Type
1.4.2 North America Neurological Biomarkers Market, by Application
1.4.3 North America Neurological Biomarkers Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenarios
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. North America Neurological Biomarkers Market by Type
3.1 North America Proteomic Market by Country
3.2 North America Genomic Market by Country
3.3 North America Metabolomic Market by Country
3.4 North America Others Market by Country
Chapter 4. North America Neurological Biomarkers Market by Application
4.1 North America Alzheimer's Disease Market by Country
4.2 North America Parkinson’s Disease Market by Country
4.3 North America Multiple Sclerosis Market by Country
Chapter 5. North America Neurological Biomarkers Market by Country
5.1 US Neurological Biomarkers Market
5.1.1 US Neurological Biomarkers Market by Type
5.1.2 US Neurological Biomarkers Market by Application
5.2 Canada Neurological Biomarkers Market
5.2.1 Canada Neurological Biomarkers Market by Type
5.2.2 Canada Neurological Biomarkers Market by Application
5.3 Mexico Neurological Biomarkers Market
5.3.1 Mexico Neurological Biomarkers Market by Type
5.3.2 Mexico Neurological Biomarkers Market by Application
5.4 Rest of North America Neurological Biomarkers Market
5.4.1 Rest of North America Neurological Biomarkers Market by Type
5.4.2 Rest of North America Neurological Biomarkers Market by Application
Chapter 6. Company Profiles
6.1 F. Hoffmann-La Roche Ltd.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.2 Bio-Rad laboratories, Inc.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expenses
6.3 Merck Group
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.3.5 Recent strategies and developments:
6.3.5.1 Partnerships, Collaborations, and Agreements:
6.4 PerkinElmer, Inc.
6.4.1 Company Overview
6.4.1 Financial Analysis
6.4.2 Segmental and Regional Analysis
6.4.3 Research & Development Expense
6.5 Shimadzu Corporation
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.6 Thermo Fisher Scientific, Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expense
6.7 BioMérieux S.A.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Segmental and Regional Analysis
6.7.4 Research & Development Expenses
6.8 Myriad Genetics, Inc.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Segmental Analysis
6.8.4 Research & Development Expenses
6.9 Quanterix Corporation
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Research & Development Expenses
6.9.5 Recent strategies and developments:
6.9.5.1 Partnerships, Collaborations, and Agreements:
6.10. Neuro-Bio Ltd.
6.10.1 Company Overview
TABLE 1 North America Neurological Biomarkers Market, 2018 - 2021, USD Million
TABLE 2 North America Neurological Biomarkers Market, 2022 - 2028, USD Million
TABLE 3 North America Neurological Biomarkers Market by Type, 2018 - 2021, USD Million
TABLE 4 North America Neurological Biomarkers Market by Type, 2022 - 2028, USD Million
TABLE 5 North America Proteomic Market by Country, 2018 - 2021, USD Million
TABLE 6 North America Proteomic Market by Country, 2022 - 2028, USD Million
TABLE 7 North America Genomic Market by Country, 2018 - 2021, USD Million
TABLE 8 North America Genomic Market by Country, 2022 - 2028, USD Million
TABLE 9 North America Metabolomic Market by Country, 2018 - 2021, USD Million
TABLE 10 North America Metabolomic Market by Country, 2022 - 2028, USD Million
TABLE 11 North America Others Market by Country, 2018 - 2021, USD Million
TABLE 12 North America Others Market by Country, 2022 - 2028, USD Million
TABLE 13 North America Neurological Biomarkers Market by Application, 2018 - 2021, USD Million
TABLE 14 North America Neurological Biomarkers Market by Application, 2022 - 2028, USD Million
TABLE 15 North America Alzheimer's Disease Market by Country, 2018 - 2021, USD Million
TABLE 16 North America Alzheimer's Disease Market by Country, 2022 - 2028, USD Million
TABLE 17 North America Parkinson’s Disease Market by Country, 2018 - 2021, USD Million
TABLE 18 North America Parkinson’s Disease Market by Country, 2022 - 2028, USD Million
TABLE 19 North America Multiple Sclerosis Market by Country, 2018 - 2021, USD Million
TABLE 20 North America Multiple Sclerosis Market by Country, 2022 - 2028, USD Million
TABLE 21 North America Neurological Biomarkers Market by Country, 2018 - 2021, USD Million
TABLE 22 North America Neurological Biomarkers Market by Country, 2022 - 2028, USD Million
TABLE 23 US Neurological Biomarkers Market, 2018 - 2021, USD Million
TABLE 24 US Neurological Biomarkers Market, 2022 - 2028, USD Million
TABLE 25 US Neurological Biomarkers Market by Type, 2018 - 2021, USD Million
TABLE 26 US Neurological Biomarkers Market by Type, 2022 - 2028, USD Million
TABLE 27 US Neurological Biomarkers Market by Application, 2018 - 2021, USD Million
TABLE 28 US Neurological Biomarkers Market by Application, 2022 - 2028, USD Million
TABLE 29 Canada Neurological Biomarkers Market, 2018 - 2021, USD Million
TABLE 30 Canada Neurological Biomarkers Market, 2022 - 2028, USD Million
TABLE 31 Canada Neurological Biomarkers Market by Type, 2018 - 2021, USD Million
TABLE 32 Canada Neurological Biomarkers Market by Type, 2022 - 2028, USD Million
TABLE 33 Canada Neurological Biomarkers Market by Application, 2018 - 2021, USD Million
TABLE 34 Canada Neurological Biomarkers Market by Application, 2022 - 2028, USD Million
TABLE 35 Mexico Neurological Biomarkers Market, 2018 - 2021, USD Million
TABLE 36 Mexico Neurological Biomarkers Market, 2022 - 2028, USD Million
TABLE 37 Mexico Neurological Biomarkers Market by Type, 2018 - 2021, USD Million
TABLE 38 Mexico Neurological Biomarkers Market by Type, 2022 - 2028, USD Million
TABLE 39 Mexico Neurological Biomarkers Market by Application, 2018 - 2021, USD Million
TABLE 40 Mexico Neurological Biomarkers Market by Application, 2022 - 2028, USD Million
TABLE 41 Rest of North America Neurological Biomarkers Market, 2018 - 2021, USD Million
TABLE 42 Rest of North America Neurological Biomarkers Market, 2022 - 2028, USD Million
TABLE 43 Rest of North America Neurological Biomarkers Market by Type, 2018 - 2021, USD Million
TABLE 44 Rest of North America Neurological Biomarkers Market by Type, 2022 - 2028, USD Million
TABLE 45 Rest of North America Neurological Biomarkers Market by Application, 2018 - 2021, USD Million
TABLE 46 Rest of North America Neurological Biomarkers Market by Application, 2022 - 2028, USD Million
TABLE 47 KEY INFORMATION – F. Hoffmann-La Roche Ltd.
TABLE 48 Key Information – Bio-Rad Laboratories, Inc.
TABLE 49 key Information – Merck GrouP
TABLE 50 key Information – PerkinElmer, Inc.
TABLE 51 Key Information – Shimadzu Corporation
TABLE 52 Key Information – Thermo Fisher Scientific, Inc.
TABLE 53 Key information – BioMérieux S.A.
TABLE 54 Key Information – Myriad Genetics, Inc.
TABLE 55 Key Information – QUANTERIX CORPORATION
TABLE 56 Key Information – Neuro-Bio Ltd.
List of Figures
FIG 1 Methodology for the research